# Add-on to Thiazolidinedione (TZD) Failures

> **NCT00683878** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 972 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin
- **DRUG:** Placebo matching Dapagliflozin
- **DRUG:** Thiazolidinedione (Pioglitazone)

## Key facts

- **NCT ID:** NCT00683878
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-01
- **Final completion:** 2010-06
- **Target enrollment:** 972 (ACTUAL)
- **Last updated:** 2017-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683878, "Add-on to Thiazolidinedione (TZD) Failures". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00683878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*